WHAT IS CLAIMED IS:

1. A method of treating and/or preventing at least one fungal infection in a mammal afflicted with at least one fungal infection which comprises administering an antifungally effective amount of a compound sufficient for such treating or preventing, and wherein the compound has the following structure:



wherein:

R_1, R_2, R_5, R_7, and R_8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C_1-C_{24} alkyl, unsaturated C_1-C_{24} alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups,

R_3, R_4, and R_6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C_1-C_{12} alkyl, unsaturated C_1-C_{12} alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups,

X_1 and X_2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and

the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond..

2. The method of Claim 1, wherein the fungal infection is selected from the group consisting of an Aspergillosis infection, blastomycosis infection, Candidiasis infection, Coccidioidomycosis infection, Cryptococcosis infection, Histopolasmosis infection, Paracoccidioidomycosis, Sporotrichosisand, and Mucormycosis infection.

3. The method of Claim 2, wherein the Aspergillosis infection is invasive pulmonary aspergillosis.

4. The method of Claim 2, wherein the Mucormycosis infection is craniofacial mucormycosis or pulmonary mucormycosis.

5. The method of Claim 2, wherein the Candidiasis infection is retrograde candidiasis of the urinary tract.

6. A pharmaceutical composition for treating or preventing fungal infection comprising an antifungally effective amount of a pharmaceutically acceptable carrier and a compound having the structure:



wherein:

R_1, R_2, R_5, R_7, and R_8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C_1-C_{24} alkyl, unsaturated C_1-C_{24} alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups,

R_3, R_4, and R_6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C_1-C_{12} alkyl, unsaturated C_1-C_{12} alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups,

X_1 and X_2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and

the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond.

7. The composition of Claim 6, wherein the fungal infection is selected from the group consisting of an Aspergillosis infection, blastomycosis infection, Candidiasis infection, Coccidioidomycosis infection, Cryptococcosis infection, Histopolasmosis infection, Paracoccidioidomycosis, Sporotrichosisand, and Mucormycosis infection.

8. The composition of Claim 7, wherein the Aspergillosis infection is invasive pulmonary aspergillosis.

9. The composition of Claim 7, wherein the Mucormycosis infection is craniofacial mucormycosis or pulmonary mucormycosis.

10. The composition of Claim 7, wherein the Candidiasis infection is retrograde candidiasis of the urinary tract.